Recently, The US FDA authorized Teva to introduce the generic counterpart of Diovan “Valsartan” tablets in the US market. * The anticipated elevation in earnings is calculated to be $29 million. On a per share basis, the EPS is computed to go up by $0.03 in 2015. Apart from entering into the generic market of Diovan, Teva is also actively moving ahead to introduce generic version of two other antibiotics in the US market. The launch of generic equivalents of Pfizer’s Zyvox and USP’s Nafcillin is expected to uplift the EPS by $0.01 in the fiscal year 2015.